Het cholinerge deficiëntiesyndroom als indicatie voor cholinesteraseremmers

Translated title of the contribution: Cholinergic deficiency syndrome as an indicator for cholinesterase inhibitors

A. W. Lemstra*, P. Eikelenboom, W. A. Van Gool

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


Cholinesterase inhibitors are licensed for the treatment of dementia in Alzheimer's disease. In clinical practice, these drugs have little effect on the cognitive symptoms of dementia. Several studies report a beneficial effect of cholinesterase inhibitors on neuropsychiatric symptoms. We hypothesise that symptoms such as the impairment of attention and concentration, anxiety, restlessness and hallucinations, delineate a specific central cholinergic deficiency syndrome. It is postulated that this syndrome crosses boundaries of nosological entities and occurs in various neurodegenerative diseases. Symptoms resulting from cholinergic deficiency might be a much better target for treatment than cognitive deficits.

Translated title of the contributionCholinergic deficiency syndrome as an indicator for cholinesterase inhibitors
Original languageDutch
Pages (from-to)2201-2203
Number of pages3
JournalNederlands Tijdschrift voor Geneeskunde
Issue number45
Publication statusPublished - 8 Nov 2003
Externally publishedYes

Cite this